GMJ Medicine
eISSN : 2626-3041
Embase
Biosis Previews
description
Volume 2, Issue 2 (2023)
GMJM 2023, 2(2): 57-61 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2022/09/20 | Accepted: 2023/02/18 | Published: 2023/04/7
Received: 2022/09/20 | Accepted: 2023/02/18 | Published: 2023/04/7
How to cite this article
Forghani N, Rahimian Boogar M, Faramarzi H. Mental and Muscle Relaxation in Water Decreases Liver Enzymes and Inflammatory Markers in Non-Alcoholic Fatty Liver Disease. GMJM 2023; 2 (2) :57-61
URL: http://gmedicine.de/article-2-254-en.html
URL: http://gmedicine.de/article-2-254-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Cell and Molecular Biology, School of Biology, College of Sciences, Tehran University, Tehran, Iran
2- School of Medical, Shiraz University of Medical Sciences, Shiraz, Iran
2- School of Medical, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract (914 Views)
Aims: Non-alcoholic fatty liver disease has increased over the past years. It occurs when liver cells begin to collect fat droplets. Liver enzymes are the best indicator for assessing liver status. The incidence of this disease in women is higher than in men, although opposite results have been reported. The effect of mental and muscle relaxation in water was investigated to evaluate changes in liver enzymes, inflammatory markers, and C-reactive protein of Non-alcoholic fatty liver disease patients.
Materials & Methods: This was a randomized clinical trial with a pretest-posttest and follow-up with the control group. Liver enzymes and inflammatory markers, including IL-6 and CRP, were measured before and after mental and muscle relaxation. The data was analyzed using an independent samples t-test, a paired t-test, and a two-way mixed ANOVA (repeated measures). Also, the correlation test was used to evaluate the correlation between age and FBS and liver enzymes.
Findings: There were significant reductions in measured indices (FBS, AST, ALT, ALP, IL-6, and CRP) within the treatment group in comparison with the control group (p<0.05). Also, there were significant differences in means of AST (p<0.001), ALT (p<0.002), ALP (p=0.021), IL-6 (p<0.001), and CRP (p=0.019) between the two groups after mental and muscle relaxation in water.
Conclusion: Mental and muscle relaxation in the water significantly improved and reduced the symptoms of NAFLD patients.
Materials & Methods: This was a randomized clinical trial with a pretest-posttest and follow-up with the control group. Liver enzymes and inflammatory markers, including IL-6 and CRP, were measured before and after mental and muscle relaxation. The data was analyzed using an independent samples t-test, a paired t-test, and a two-way mixed ANOVA (repeated measures). Also, the correlation test was used to evaluate the correlation between age and FBS and liver enzymes.
Findings: There were significant reductions in measured indices (FBS, AST, ALT, ALP, IL-6, and CRP) within the treatment group in comparison with the control group (p<0.05). Also, there were significant differences in means of AST (p<0.001), ALT (p<0.002), ALP (p=0.021), IL-6 (p<0.001), and CRP (p=0.019) between the two groups after mental and muscle relaxation in water.
Conclusion: Mental and muscle relaxation in the water significantly improved and reduced the symptoms of NAFLD patients.
Keywords:
| | Full-Text (HTML) (27 Views)
References
1. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009;48(1):1-26. [Link] [DOI:10.1016/j.plipres.2008.08.001]
2. FerreiraVS, Pernambuco RB, Lopes EP, Morais C, Rodrigues MC, Arruda M, et al. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetesmellitus. Arq Bras Endocrinol Metab. 2010;54(4):362-8. [Link] [DOI:10.1590/S0004-27302010000400004]
3. Neuman MG, Malnick S, Maor Y, Nanau RM, Melzer E, Ferenci P, et al. Alcoholic liver disease: Clinical and translational research. Exp Mol Pathol. 2015;99(3):596-610. [Link] [DOI:10.1016/j.yexmp.2015.09.001]
4. Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008;9(8):616-22. [Link] [DOI:10.1631/jzus.B0720016]
5. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: The role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol. 2009;6(4):236-47. [Link] [DOI:10.1038/nrgastro.2009.33]
6. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-85. [Link] [DOI:10.1111/j.1365-2036.2011.04724.x]
7. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology. 2011;140:124-31. [Link] [DOI:10.1053/j.gastro.2010.09.038]
8. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112-7. [Link] [DOI:10.7326/0003-4819-132-2-200001180-00004]
9. Lonardo A, Carani C, Carulli N, Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol. 2006;44(6):1196-207. [Link] [DOI:10.1016/j.jhep.2006.03.005]
10. Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65-S76. [Link] [DOI:10.1016/j.jhep.2015.02.041]
11. Akyüz F, Demir K, Özdil S, Aksoy N, Poturoğlu Ş, İbrişim D, et al. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig Dis Sci. 2007;52(9):2359-67. [Link] [DOI:10.1007/s10620-006-9145-x]
12. Okita M, Hayashi M, Sasagawa T, Takagi K, Suzuki K, Kinoyama S, et al. Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition. 2001;17(7-8):542-7. [Link] [DOI:10.1016/S0899-9007(01)00543-3]
13. Hariri M, Zohdi S. Effect of vitamin d on non-alcoholic fatty liver disease: A systematic review of randomized controlled clinical trials. Int J Prev Med. 2019;10:14. [Link] [DOI:10.4103/ijpvm.IJPVM_499_17]
14. Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G, Gunsar F, et al. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology. 2009;9:16. [Link] [DOI:10.1186/1471-230X-9-16]
15. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring). 2008;16(6):1394-9. [Link] [DOI:10.1038/oby.2008.64]
16. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18(8):727-35. [Link] [DOI:10.3748/wjg.v18.i8.727]
17. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis. 2000;148(2):209-14. [Link] [DOI:10.1016/S0021-9150(99)00463-3]
18. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38(2):413-9. [Link] [DOI:10.1053/jhep.2003.50316]
19. Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haa land T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44(6):1167-74. [Link] [DOI:10.1016/j.jhep.2006.02.011]
20. Mooventhan A, Nivethitha L. Scientific evidence-based effects of hydrotherapy on various systems of the body. N Am J Med Sci. 2014;6(5):199-209. [Link] [DOI:10.4103/1947-2714.132935]
21. McPherson RA, Pincus MR. Henry's clinical diagnosis and management by laboratory methods. Elsevier Health Sciences; 23rd ed. 2016:P1584. [Link]
22. Androlli TE. Principles of the Internal Medicine of Cecil. Tehran: Taymoor Zadeh Publications, 2010. [Persian] [Link]
23. Ferolla SM, Armiliato G N, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7(3):559-65. [Link] [DOI:10.4254/wjh.v7.i3.559]
24. Rahmioglu N, Andrew T, Cherkas L, Surdulescu G, Swaminathan R, Spector T, et al. Epidemiology and genetic epidemiology of the liver function test proteins. PLoS One. 2009;4(2):e4435. [Link] [DOI:10.1371/journal.pone.0004435]
25. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: Population based study. Ann Hepatol. 2007;6(3):161-3. [Link] [DOI:10.1016/S1665-2681(19)31922-2]
26. Sekhavati E, Rahimian M, Afkari R, Kasharafifard S, Parsaei MV, Lotfi MF, et al. The study of effectiveness of progressive muscle relaxation to reduce symptoms in women with migraine headache. R J Med Sci. 2016;10(3):175-84. [Link]
27. Skrypnik D, Ratajczak M, Karolkiewicz J, Mądry E, Pupek-Musialik D, Hansdorfer-Korzon, et al. Effects of endurance and endurance-strength exercise on biochemical parameters of liver function in women with abdominal obesity. Biomed Pharmacother. 2016;80:1-7. [Link] [DOI:10.1016/j.biopha.2016.02.017]
28. Chitturi S, Farrell GC, George J. Non‐alcoholic steatohepatitis in the Asia-Pacific region: Future shock? J Gastroenterol Hepatol. 2004;19(4):368-74. [Link] [DOI:10.1111/j.1440-1746.2003.03252.x]
29. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98(4):1154-62. [Link] [DOI:10.1152/japplphysiol.00164.2004]
30. Abd El-Kader SM, Al-Jiffri OH, Al-Shreef FM. Markers of liver function and inflammatory cytokines modulation by aerobic versus resisted exercise training for nonalcoholic steatohepatitis patients. Afr Health Sci. 2014;14(3):551-7. [Link] [DOI:10.4314/ahs.v14i3.8]
31. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatol. 2012;55(6):1738-45. [Link] [DOI:10.1002/hep.25548]